Zasocitinib tops deucravacitinib. 3 years of nemolizumab. New targets in lupus and HS. EADV 2026, at a glance โ
hubs.li/Q04FClwb0
1
286
๐ฅ๐ฌ Q&A: Skin cancer prevention doesn't end when summer does.
๐ Read the full Q&A: hubs.li/Q04FJDW30
#SkinCancerPrevention #SunProtection #PatientEducation #Dermatology
152
๐ก EXPERT INSIGHTS: How should clinicians interpret cross-trial efficacy data when selecting treatments for alopecia areata?
๐ Read more: Weighing Cross-Trial Data and Patient Timelines in Alopecia Areata Treatment
#AlopeciaAreata #JAKInhibitors #HairLoss #Dermatology
1
306
๐ฅ EXPERT PERSPECTIVES: Could severe atopic dermatitis affect more than just the skin in children?
๐ Watch now: hubs.li/Q04FJGKF0
#ExpertPerspectives #AtopicDermatitis #PediatricDermatology #Dupilumab
5
341
๐ THE AESTHETIC EDGE: Bioelements and Celluma are joining forces to bring LED light therapy into professional facial treatments.
๐ Read more: hubs.li/Q04FJB2T0
#AestheticDermatology #LEDLightTherapy #SkinCare #Dermatology
1
278
๐ก EXPERT COMMENTARY: Could a more comprehensive approach to indoor tanning prevention help reduce melanoma risk?
๐ Read more: hubs.li/Q04FJBRs0
#MelanomaPrevention #SkinCancerAwareness #IndoorTanning #Dermatology
243
Can AI speed up skin cancer pathways? How many viral "glass skin" TikToks get it wrong?
Swipe through EADV 2026 highlights โ
hubs.li/Q04FBZn40
1
323
๐ก EXPERT INSIGHTS: Mark G. Lebwohl, MD, discusses anticipated monitoring requirements, the differences between oral and injectable therapies, and how disease severity and patient preferences can guide individualized treatment decisions.
๐ฅ Watch now: hubs.li/Q04FpLnW0
4
517
๐จ FDA UPDATE: The FDA has implemented updated iPLEDGE REMS requirements for isotretinoin, introducing changes to the program designed to prevent fetal exposure during treatment.
๐ Read more: hubs.li/Q04FpM3w0
#Isotretinoin #iPLEDGE #FDAUpdate #Dermatology
1
5
1,320
๐ CLINICAL TRIAL UPDATE: Aclaris Therapeutics' investigational antibody bosakitug failed to meet the primary and secondary efficacy end points in a phase 2 trial for moderate to severe atopic dermatitis.
hubs.li/Q04FpG-b0
#Bosakitug #AclarisTherapeutics
2
515
๐ JOURNAL DIGEST: Stay up to date with the latest research shaping dermatology practice in this week's Dermatology Times Journal Digest.
๐ Read the November 16 edition: hubs.li/Q04FpHJc0
#JournalDigest #DermatologyResearch #Dermatology
1
308
In the latest episode of Don't Be Rash, host Andrew Krakowski, MD, is joined by Joseph Lam, MD, FRCPC, of BC Children's Hospital, to discuss how clinicians can distinguish benign birthmarks from early signs of NF1 and related conditions.
hubs.li/Q04FgndW0
351
๐ก EXPERT INSIGHTS: Type 2 inflammation plays a central role in multiple dermatologic diseases, creating opportunities for more targeted treatment approaches.
hubs.li/Q04FgVGk0
Pritelivir approved. First joint HS guidelines. Zasocitinib vs deucravacitinib. October in dermatology, at a glance โ
hubs.li/Q04F2F9Y0
How early should clinicians consider biologic therapy for children with atopic dermatitis? Mark G. Lebwohl, MD, of the Icahn School of Medicine at Mount Sinai, discusses the importance of skin barrier protection.
hubs.li/Q04FgSJQ0
The latest episode of #DontBeRash is now live!
In this episode, host Dr. Krakowski sits down with leading expert Dr. Joseph Lam for a deep dive into how CALM count, size, age, and associated findings separate benign spots from NF1 and its mimics.
hubs.li/Q04Fc1Kb0
Can castor oil grow hair? Does face taping prevent wrinkles?
Swipe through October's Social Media Mythbusters and top stories โ
hubs.li/Q04F2ywk0
1
312
๐ก EXPERT INSIGHTS: For patients living with hidradenitis suppurativa (HS), support can extend beyond traditional medical treatment.
Read more: hubs.li/Q04F8-Gk0
#HidradenitisSuppurativa #PetTherapy #MentalHealth #Dermatology
1
379
โญ๏ธ CASE-BASED INSIGHTS: Selecting a hedgehog inhibitor for advanced basal cell carcinoma (BCC) requires more than evaluating efficacy alone.
Read more: hubs.li/Q04F8XcD0
#BasalCellCarcinoma #BCC #SkinCancer #Dermatology
2
486
๐ NEW DATA: Phase 3 findings support risankizumab (Skyrizi) as a potential treatment option for pediatric patients with moderate to severe plaque psoriasis.
Read more: hubs.li/Q04F8YgX0
#Risankizumab #PediatricPsoriasis #Psoriasis #Dermatology
3
768








